TrueBlue Clinical Study - Investigating the Use of a Mobile Phone App TrueBlue for Monitoring Depression and Anxiety
Key facts
- Who runs it
- BlueSkeye AI
- Where
- United Kingdom2 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Recruiting
- People taking part
- 125 people, planned
- Started
- 1 Oct 2024
- Expected to end
- 30 Dec 2026
- Type of study
- Interventional
- Treatments tested
- TrueBlue App
- Record updated
- 19 September 2025
Who can take part
- Age
- 18 years and older
- Sex
- Women only
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 8 criteriaShow less
Who can take part
- 18 years or older
- Fluent in spoken and written English
- Has capacity to provide consent
- At least 12 weeks pregnant or less than 12 weeks postpartum
- Access to internet connectivity
- Access to a compatible smart phone device (for up to 10 participants, where needed through not having a personal device, this access may be provided through the study team)
- Has a current GP within Nottinghamshire
Who cannot take part
- ● Current clinically diagnosed psychiatric disorder other than depression; Previous history of a clinically diagnosed psychiatric disorder, other than depression and generalised anxiety disorder (including previous Psychosis, Bipolar Disorder, Personality Disorder, Substance Abuse Disorders, Eating Disorders); Clinical diagnosis of an Autistic Spectrum Disorder, Attention Deficit Hyperactivity Disorder, Parkinson's Disease or other current Neurological Disorder
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This trial will assess the safety, feasibility, acceptability, usability and agreement with validated scales of an automated mood monitoring App (TrueBlue), in adult, perinatal participants (recruited between 12 weeks of pregnancy and 12 weeks post-partum), recruited across multiple sites in Nottinghamshire, United Kingdom (UK). An initial within-study pilot phase will assess key aspects of the study including recruitment rate, usability issues and a detailed understanding of any device related adverse events; prior to full recruitment of a total 125 participants over a total 14-month period.
The group in the trial
- Device Related Adverse EventsOther group
The primary aim of the study is to demonstrate that use of the TrueBlue app to monitor depression is safe
Treatment: TrueBlue App
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 19 September 2025